Results for this period
Interim period (second quarter)1 October 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased as a result of making Faskia Holdings and 3 subsidiaries consolidated subsidiaries. In the Medical Total Solution Business, sales increased despite a decline in bundled sales, due to higher sales in other areas, while profit declined because lower-margin sales resulting from a decrease in large, high-margin projects reduced the profit margin. In the Remote Diagnostic Imaging Services Business, profit increased on the effect of higher sales.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥24,280 million (YoY +87.6%) |
| Operating profit | ¥526 million (YoY +6.0%) |
| Ordinary income | ¥507 million (YoY -1.1%) |
| Profit attributable to owners of the parent | ¥235 million (YoY -31.5%) |
| Net income per share | ¥39.82 |
| Equity ratio | End of the current fiscal period 21.6 / End of previous period 51.8 |
| Total assets | ¥26,577 million |
| Net assets | ¥5,924 million |
| Cash flows from operating activities | ¥1,869,190 thousand |
| Cash flows from investing activities | ¥-3,809,945 thousand |
| Cash flows from financing activities | ¥4,725,147 thousand |
| Cash and cash equivalents at end of period | ¥7,531,222 thousand |
| Full-year earnings forecast | Net Sales ¥44,500 million (YoY +107.1%) / Operating profit ¥680 million (YoY +135.9%) / Ordinary income ¥610 million (YoY +97.5%) / Net income ¥230 million (YoY +50.5%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥44,500 million / Operating profit Not disclosed → ¥680 million / Ordinary income Not disclosed → ¥610 million / Net income Not disclosed → ¥230 million |
| Annual Dividend Forecast | ¥17 → ¥17（0.0%） |
| Segment revenue | Medical Total Solution Business ¥12,475,689 thousand (YoY +1.1%), Remote Diagnostic Imaging Services Business ¥412,436 thousand (YoY +0.7%), Minimally Invasive Medical Device Sales Business ¥10,189,687 thousand, Rental Business ¥317,247 thousand |
| Segment profit | Medical Total Solution Business ¥304,813 thousand (YoY -32.7%), Remote Diagnostic Imaging Services Business ¥41,523 thousand (YoY +0.4%), Minimally Invasive Medical Device Sales Business ¥183,981 thousand, Rental Business ¥37,430 thousand |
| Depreciation and amortization | ¥198,383 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 4 / Company name ファスキアホールディングス株式会社, 株式会社フォーム, 株式会社シンコム, 中京三洋株式会社 / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 5,922,000 |
| Treasury Shares at Period-End | 237 |
| Factors Behind Changes in Business Performance | Net sales increased as a result of making Faskia Holdings and 3 subsidiaries consolidated subsidiaries. In the Medical Total Solution Business, sales increased despite a decline in bundled sales, due to higher sales in other areas, while profit declined because lower-margin sales resulting from a decrease in large, high-margin projects reduced the profit margin. In the Remote Diagnostic Imaging Services Business, profit increased on the effect of higher sales. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company expanded its business scale by making Faskia Holdings and 3 subsidiaries consolidated subsidiaries. In the Medical Total Solution Business, sales from bundled sales associated with the construction or relocation of medical institutions and other facilities, which had been the core business, declined, but sales increased in other areas. The main factor behind the decline in operating profit was a decrease in gross profit caused by a lower profit margin resulting from a decrease in large, high-margin projects.